These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis. Kim ST; Lee J; Hong M; Park K; Park JO; Ahn T; Park SH; Park YS; Lim HY; Sun JM; Ahn JS; Ahn MJ; Kim HC; Sohn TS; Choi DI; Cho JH; Heo JS; Kwon W; Uhm SW; Lee H; Min BH; Hong SN; Kim DH; Jung SH; Park W; Kim KM; Kang WK; Park K Oncotarget; 2015 Oct; 6(32):33358-68. PubMed ID: 26396172 [TBL] [Abstract][Full Text] [Related]
23. How are we evaluating the cost-effectiveness of companion biomarkers for targeted cancer therapies? A systematic review. Seo MK; Cairns J BMC Cancer; 2021 Sep; 21(1):980. PubMed ID: 34470603 [TBL] [Abstract][Full Text] [Related]
24. Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers. Jahn A; Rump A; Widmann TJ; Heining C; Horak P; Hutter B; Paramasivam N; Uhrig S; Gieldon L; Drukewitz S; Kübler A; Bermudez M; Hackmann K; Porrmann J; Wagner J; Arlt M; Franke M; Fischer J; Kowalzyk Z; William D; Weth V; Oster S; Fröhlich M; Hüllein J; Valle González C; Kreutzfeldt S; Mock A; Heilig CE; Lipka DB; Möhrmann L; Hanf D; Oleś M; Teleanu V; Allgäuer M; Ruhnke L; Kutz O; Knurr A; Laßmann A; Endris V; Neumann O; Penzel R; Beck K; Richter D; Winter U; Wolf S; Pfütze K; Geörg C; Meißburger B; Buchhalter I; Augustin M; Aulitzky WE; Hohenberger P; Kroiss M; Schirmacher P; Schlenk RF; Keilholz U; Klauschen F; Folprecht G; Bauer S; Siveke JT; Brandts CH; Kindler T; Boerries M; Illert AL; von Bubnoff N; Jost PJ; Metzeler KH; Bitzer M; Schulze-Osthoff K; von Kalle C; Brors B; Stenzinger A; Weichert W; Hübschmann D; Fröhling S; Glimm H; Schröck E; Klink B Ann Oncol; 2022 Nov; 33(11):1186-1199. PubMed ID: 35988656 [TBL] [Abstract][Full Text] [Related]
25. The business of genomic testing: a survey of early adopters. Crawford JM; Bry L; Pfeifer J; Caughron SK; Black-Schaffer S; Kant JA; Kaufman JH Genet Med; 2014 Dec; 16(12):954-61. PubMed ID: 25010053 [TBL] [Abstract][Full Text] [Related]
29. Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial. Harttrampf AC; Lacroix L; Deloger M; Deschamps F; Puget S; Auger N; Vielh P; Varlet P; Balogh Z; Abbou S; Allorant A; Valteau-Couanet D; Sarnacki S; Gamiche-Rolland L; Meurice G; Minard-Colin V; Grill J; Brugieres L; Dufour C; Gaspar N; Michiels S; Vassal G; Soria JC; Geoerger B Clin Cancer Res; 2017 Oct; 23(20):6101-6112. PubMed ID: 28733441 [No Abstract] [Full Text] [Related]
30. Personalized Medicine: Genomics Trials in Oncology. Hayes DF; Schott AF Trans Am Clin Climatol Assoc; 2015; 126():133-43. PubMed ID: 26330667 [TBL] [Abstract][Full Text] [Related]
31. Personalized cancer therapy-leveraging a knowledge base for clinical decision-making. Dumbrava EI; Meric-Bernstam F Cold Spring Harb Mol Case Stud; 2018 Apr; 4(2):. PubMed ID: 29212833 [TBL] [Abstract][Full Text] [Related]
32. Molecular profiling for precision cancer therapies. Malone ER; Oliva M; Sabatini PJB; Stockley TL; Siu LL Genome Med; 2020 Jan; 12(1):8. PubMed ID: 31937368 [TBL] [Abstract][Full Text] [Related]
33. Twenty-First Century Precision Medicine in Oncology: Genomic Profiling in Patients With Cancer. Borad MJ; LoRusso PM Mayo Clin Proc; 2017 Oct; 92(10):1583-1591. PubMed ID: 28982488 [TBL] [Abstract][Full Text] [Related]
34. Utility of Reverse-Phase Protein Array for Refining Precision Oncology. Masuda M; Yamada T Adv Exp Med Biol; 2019; 1188():239-249. PubMed ID: 31820392 [TBL] [Abstract][Full Text] [Related]
35. Complexity of genome sequencing and reporting: Next generation sequencing (NGS) technologies and implementation of precision medicine in real life. Morganti S; Tarantino P; Ferraro E; D'Amico P; Viale G; Trapani D; Duso BA; Curigliano G Crit Rev Oncol Hematol; 2019 Jan; 133():171-182. PubMed ID: 30661654 [TBL] [Abstract][Full Text] [Related]
36. Alison's Story--A Cautionary Tale in the Age of Genomic Medicine. Burn J Surg Oncol Clin N Am; 2015 Oct; 24(4):635-7. PubMed ID: 26363533 [TBL] [Abstract][Full Text] [Related]
37. Molecular Tumor Boards in Clinical Practice. Luchini C; Lawlor RT; Milella M; Scarpa A Trends Cancer; 2020 Sep; 6(9):738-744. PubMed ID: 32517959 [TBL] [Abstract][Full Text] [Related]
38. Pediatric oncology enters an era of precision medicine. Seibel NL; Janeway K; Allen CE; Chi SN; Cho YJ; Glade Bender JL; Kim A; Laetsch TW; Irwin MS; Takebe N; Tricoli JV; Parsons DW Curr Probl Cancer; 2017; 41(3):194-200. PubMed ID: 28343740 [TBL] [Abstract][Full Text] [Related]
39. "Somatic" Tumor Genomic Profiling and Potential Germline Implications: Ethical Considerations for Children with Cancer. Knapp E J Law Med Ethics; 2020 Dec; 48(4):778-783. PubMed ID: 33404327 [No Abstract] [Full Text] [Related]
40. Matching methods in precision oncology: An introduction and illustrative example. Weymann D; Laskin J; Jones SJM; Lim H; Renouf DJ; Roscoe R; Schrader KA; Sun S; Yip S; Marra MA; Regier DA Mol Genet Genomic Med; 2021 Jan; 9(1):e1554. PubMed ID: 33237632 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]